



Pergamon

Bioorganic & Medicinal Chemistry 9 (2001) 2341–2346

BIOORGANIC &
MEDICINAL
CHEMISTRY

Direct Measurement of Pyrimidine C6-hydrate Stability

K. Nolan Carter and Marc M. Greenberg*

Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA

Received 1 February 2001; accepted 16 April 2001


Dedicated to Professor Peter B. Dervan.

Abstract—Pyrimidine C6-hydrates are produced via UV-irradiation and undergo dehydration upon standing. The stability of these compounds has a direct bearing on their genotoxicity. The rate constants for elimination from 5'-benzoylated derivatives of 5,6-dihydro-5-hydroxythymidine (**6**) and 5,6-dihydro-5-hydroxy-2'-deoxyuridine (**9**) were measured directly via HPLC. The rate constants for dehydration increase from pH 6.0 to 8.0. The half-lives for **6** and **9** at pH 7.4 and 37 °C are 46.5 and 24.4 h, respectively. Deglycosylation is not observed, even upon heating at 90 °C. These observations reinforce proposals that pyrimidine hydrates are sufficiently long-lived that they can exert significant effects on biological systems. © 2001 Elsevier Science Ltd. All rights reserved.


Pyrimidine hydrates are produced by a variety of reaction pathways that are populated when nucleic acids are exposed to ionizing radiation.¹ Thymidine C5-hydrate (**1**) is produced by hydroxyl radical addition under O₂ deficient conditions.^{1,2} The C6-hydrates of deoxycytidine (**2**) and thymidine (**3**) are the major non-dimeric lesions produced upon UV-irradiation.^{3,4} 5,6-Dihydro-6-hydroxy-2'-deoxyuridine (**4**) is produced in DNA from hydrolysis of the C6-hydrate of dC (**2**).^{5–7} The C6-hydrates may also be produced upon hydration of nucleobase cation radicals.⁸ The biological relevance of pyrimidine hydrates is underscored by their excision by base excision repair enzymes, such as endonuclease III.^{5–7,9–12} Furthermore, thymidine C5-hydrate (**1**) is a potent inhibitor of DNA polymerase I (Klenow exo⁻ fragment) and **2** is a premutagenic lesion in vitro.¹³ The pyrimidine C6-hydrates undergo dehydration, and their chemical instability potentiates their ability to influence the fidelity of replication and transcription. We wish to report on our studies concerning the direct measurement of dehydration in 5'-protected pyrimidine C6-hydrates.

Our interest in the chemical stability of pyrimidine C6-hydrates was cultivated by our studies on 5,6-dihydropyrimidin-6-yl radicals (e.g., **5**) from which pyrimidine C6-hydrates are formed under aerobic conditions. Investigations of radical mediated DNA damage

necessitated that we understand the lability of **3** and **4**. Direct measurement of dehydration rates of thymine and uracil C6-hydrates have been reported.³ However, we were uncertain if one could safely extrapolate from studies on free bases where N-1 is not alkylated to nucleosides, and in turn, DNA. Dehydration rates of thymidine and deoxyuridine C6-hydrates have been measured in DNA using a combined enzymatic and HPLC assay.^{6,7,11} In this assay, the amount of modified free base that is released by endonuclease III is measured by HPLC as a function of time. However, this approach would obscure any deglycosylation, which may compete with dehydration. Consequently, we set out to determine if deglycosylation competes with dehydration in nucleoside C6-hydrates, and to measure rates of dehydration directly in **3** and **4**.




*Corresponding author. Tel.: +1-970-491-7972; fax: +1-970-491-1801; e-mail: mgreenbe@lamar.colostate.edu



Results and Discussion


Chemical stability studies of single diastereomers of **3** and **4** were carried out using 5'-benzoyl derivatives. The 5'-benzoyl group was incorporated in order to enhance detection by UV-absorption, to facilitate purification, and to remove any possible role that a free 5'-hydroxyl group might play in the chemical stability of the C6-hydrates. There is precedent for involvement of the primary hydroxyl group in the rearrangement of formamidopyrimidine deoxynucleosides at pH 7 and dihydropyrimidines under acidic conditions.^{14,15} Such reactions diminish the relevance of monomer studies to DNA where the presence of the 5'-phosphate diester group prohibits rearrangements of this type.



Single diastereomers of benzoylated C6-hydrates of thymidine (**6** and **7**) and 2'-deoxyuridine (**8** and **9**) were synthesized via modification of procedures reported for the free nucleosides.¹⁶ High yields of the bromohydrin precursors were obtained using *N*-bromosuccinimide as

a source of Br₂ and CaCO₃ to buffer the reactions (Scheme 1). Following separation of the diastereomeric *trans*-bromohydrins, the respective benzoylated C6-hydrates were obtained via Zn⁰/AcOH reduction. Isolated yields of 5,6-dihydro-6-hydroxy-2'-deoxyuridines (**8**, **9**) were compromised due to facile elimination under the reaction and purification conditions. Careful chromatography provided the 6*S*-diastereomer (**8**) without any contamination of 5'-benzoyl-2'-deoxyuridine (**11**); whereas samples of **9** were contaminated by ~5% of **11**.

Stereochemistry in the dihydropyrimidine rings of the bromohydrins of both pyrimidines and C6-hydrates of thymidine were determined by ¹H NMR spectroscopy using analogous compounds as a frame of reference. Examination of the ¹H NMR spectra of the bromohydrins and C6-hydrates of deoxyuridine, as well as the 6-hydroperoxy-5-hydroxydihydrothymidines and 5-hydroperoxy-6-hydroxydihydrothymidines consistently indicated a greater difference in the chemical shifts of the diastereotopic H_{2'}-protons in the 6*S*-diastereomers than the 6*R*-diastereomers.^{17,18} The pro-*S* H_{2'}-proton is consistently shifted further downfield relative to the respective pro-*R* proton in the 6*S*-diastereomers than in the 6*R*-diastereomers. Stereochemical assignments of the modified thymidines mentioned above were corroborated by their reduction to the thymidine glycols, for which single crystal X-ray diffraction data is available.¹⁹ This chemical shift pattern was identified in diastereomeric pairs of bromohydrins (**12–15**) and 5'-benzoyl C6-hydrates (**6–9**) (Table 1). NOE experiments were carried out on **6**, **7**, and **12–15** in order to provide additional evidence for these stereochemical assignments. The results of these experiments were consistent with the interpretation of the chemical shift pattern. When comparing pairs of diastereomers (e.g., **6** and **7**) irradiation of H₆ produced a larger NOE at the pro-*S* H_{2'}-proton in the compound believed to contain the *R*-configuration at the C6-position (based upon chemical shifts of H_{2'}-protons) and a smaller NOE at the H_{5'}-protons. These qualitative trends were also observed in the other two pairs of diastereomers that were examined (Table 1).



Scheme 1. (a) NBS, CaCO₃, THF/H₂O; (b) Zn/HOAc, THF/H₂O.

over the course of 5 days. The rate constant for dehydration increased significantly as the pH was increased to 8.0. The dehydration reaction also showed a dependence on buffer concentration, which is consistent with general base catalysis. Finally, the decrease in half-life for **6** as the solvent polarity increased from 50% H₂O to 95% H₂O is also consistent with the anticipated negative charge buildup in the transition state.

Similar behavior was observed for the C6-hydrate of 2'-deoxyuridine (**9**). As predicted based upon previous experiments in biopolymers, dehydration from **9** was significantly faster than from the thymidine analogue (Table 3). The higher rate of dehydration observed in the 2'-deoxyuridine analogue compared to **6** is consistent with the anticipated higher acidity of the C5-proton in these compounds. The half-life for elimination at 37 °C was 24.4 and 7.2 h at pH 7.4 and 8.0, respectively. This is very close to that measured for 5,6-dihydro-6-hydroxy-2'-deoxyuridine in DNA when it is base-paired to 2'-deoxyadenosine.⁶

Conclusion

These studies support previous investigations regarding the stability of pyrimidine C6-hydrates in DNA, indicating that the repair of such lesions is important in order to avoid their potential deleterious biological effects. In addition, the facile and quantitative dehydration of **6–9** at higher temperatures indicates that this reaction will be a useful tool for manipulating tandem nucleic acids containing these lesions.

Experimental

All reactions were carried out in oven-dried glassware under an atmosphere of argon or nitrogen unless otherwise noted. THF was freshly distilled from Na/benzophenone ketyl. Dichloromethane, DMF, and

triethylamine were distilled from CaH₂. Acetonitrile was passed through CuSO₄ and then distilled from CaH₂. *N*-Bromosuccinimide (NBS) was recrystallized from H₂O.

5,6-Dihydro-5-bromo-6-hydroxy-2'-deoxyuridine (14 and 15). CaCO₃ (407 mg, 4.06 mmol) and NBS (578 mg, 3.25 mmol) were added to solution of 5'-benzoyl-2'-deoxyuridine (**11**, 900 mg, 2.71 mmol) in 3:1 THF/H₂O (21 mL) at 0 °C. The solution was allowed to warm to ambient temperature and stirred for 6 h. The reaction mixture was filtered through Celite and concentrated. The crude mixture was subjected to silica gel flash chromatography (2–10% MeOH/CHCl₃) to yield **15** (489 mg, 42%) and **14** (407 mg, 35%) as white foams. **15**: ¹H NMR (MeOH-*d*₄) δ 8.07–8.03 (m, 2H), 7.67–7.61 (m, 1H), 7.53–7.48 (m, 2H), 6.25 (t, *J* = 6.6 Hz, 1H), 5.31 (d, *J* = 2.4 Hz, 1H), 4.53 (d, *J* = 4.2 Hz, 2H), 4.46–4.42 (m, 1H), 4.21 (d, *J* = 2.4 Hz, 1H), 4.14 (dd, *J* = 8.1, 4.2 Hz), 2.31–2.27 (m, 1H), 2.20–2.16 (m, 1H); ¹³C NMR (MeOH-*d*₄) δ 168.1, 167.9, 152.4, 134.6, 131.2, 130.7, 129.9, 86.1, 85.4, 77.9, 72.5, 66.0, 41.8, 40.2; IR (film) 3431, 1700, 1465, 1273, 1087 cm⁻¹; HR-MS (FAB) calcd (M + H) 431.0277, found 431.0285. **14**: ¹H NMR (MeOH-*d*₄) δ 8.07–8.05 (m, 2H), 7.65–7.60 (m, 1H), 7.52–7.47 (m, 2H), 6.24 (t, *J* = 6.9 Hz, 1H), 5.28 (d, *J* = 2.1 Hz, 1H), 4.54–4.41 (m, 3H), 4.17 (d, *J* = 2.1 Hz, 1H), 4.14–4.10 (m, 1H), 2.47–2.38 (m, 1H), 2.19–2.14 (m, 1H); ¹³C NMR (MeOH-*d*₄) δ 168.2, 167.9, 152.3, 134.6, 131.3, 130.8, 129.8, 85.6, 84.7, 77.6, 72.4, 65.8, 41.4, 38.9; IR (film) 3396, 1698, 1452, 1276, 1090 cm⁻¹; HR-MS (FAB) calcd (M + H) 431.0277, found 431.0279.

5,6-Dihydro-5-bromo-6-hydroxythymidine (12 and 13). To a solution of 5'-benzoyl thymidine (**10**, 1.00 g, 2.89 mmol) in 3:1 THF/H₂O (28 mL) at 0 °C was added CaCO₃ (434 mg, 4.33 mmol) and NBS (616 mg, 3.46 mmol) as described above for the preparation of **14** and **15**. The reaction mixture was stirred for 0.5 h at 0 °C and then allowed to warm to ambient temperature where it was stirred for an additional 2 h. The reaction mixture was filtered through Celite and concentrated. The crude reaction mixture was purified via silica gel flash chromatography (2–10% MeOH/CHCl₃) to afford **12** (701 mg, 55%) and **13** (247 mg, 19%) as a partially separable mixture of diastereomers. **12**: ¹H NMR (MeOH-*d*₄) δ 8.09–8.07 (m, 2H), 7.65–7.61 (m, 1H), 7.52–7.48 (m, 2H), 6.25 (t, *J* = 5.5 Hz, 1H), 5.15 (s, 1H), 4.56 (dd, *J* = 9.0, 3.0 Hz, 1H), 4.13–4.10 (m, 1H), 2.48–2.42 (m, 1H), 2.19–2.14 (m, 1H), 1.69 (s, 3H); ¹³C NMR (DMSO-*d*₆) δ 167.7, 165.7, 150.7, 133.5, 129.6, 129.2, 128.8, 84.0, 83.1, 78.9, 70.6, 65.3, 55.3, 38.1, 22.5; IR (film) 3446, 1701, 1466, 1273, 1070 cm⁻¹; HR-MS (FAB) calcd 445.0433 (M + H), found 445.0447. **13**: ¹H NMR (MeOH-*d*₄) δ 8.09–8.07 (m, 2H), 7.67–7.63 (m, 1H), 7.54–7.50 (m, 2H), 6.29 (t, *J* = 5.2 Hz, 1H), 5.17 (s, 1H), 4.62 (dd, *J* = 9.0, 2.4 Hz, 1H), 4.51–4.47 (m, 2H), 4.18–4.15 (m, 1H), 2.45–2.39 (m, 1H), 2.22–2.16 (m, 1H), 1.64 (s, 3H); ¹³C NMR (DMSO-*d*₆) δ 167.8, 165.6, 150.4, 133.5, 129.6, 129.4, 128.8, 83.2, 82.5, 78.8, 70.2, 64.3, 54.3, 37.1, 22.5; IR (film) 3396, 1700, 1452, 1275, 1087 cm⁻¹; HR-MS (FAB) calcd 445.0433 (M + H), found 445.0438.




Figure 1. Disappearance of **6** as a function of time at 37 °C.

5R,6S-Dihydro-6-hydroxy thymidine (6). To a solution of 5,6-dihydro-5-bromo-6-hydroxy thymidine **12** (100 mg, 0.226 mmol) in 3:1 THF/H₂O at 0 °C was added zinc dust (46 mg, 1.31 mmol) in acetic acid (24 mg, 0.41 mmol). The reaction was stirred at 0 °C for 20 min, filtered through Celite and concentrated at ambient temperature. The crude reaction mixture was purified via silica gel flash chromatography (2% MeOH/CHCl₃) to afford **6** (23 mg, 28%) as a white residue; ¹H NMR (MeOH-*d*₄) δ 8.08–8.05 (m, 2H), 7.66–7.61 (m, 1H), 7.53–7.48 (m, 2H), 6.27 (t, *J* = 6.3 Hz, 1H), 5.10 (d, *J* = 3.0 Hz, 1H), 4.56–4.43 (m, 3H), 4.06 (dd, *J* = 8.7, 3.9 Hz, 1H), 2.73–2.65 (m, 1H), 2.53–2.43 (m, 1H), 2.18–2.10 (m, 1H), 1.07 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (MeOH-*d*₄) δ 173.8, 167.9, 154.0, 134.6, 131.2, 130.8, 129.9, 85.5, 84.5, 76.8, 72.5, 65.7, 43.1, 38.5, 10.5; IR (film) 3445, 3231, 2929, 2857, 1709, 1462, 1256, 1215, 1125, 1028, 835; HR-MS (FAB) calcd (M + H) 365.1349, found 365.1352.

5S,6R-Dihydro-6-hydroxy thymidine (7). Using the same general procedure for the preparation of **7**, **13** (100 mg, 0.226 mmol) was treated with zinc dust (46 mg, 1.31 mmol) and acetic acid (24 mg, 0.41 mmol). Purification of the crude product by silica gel flash chromatography (2% MeOH/CHCl₃) afforded **7** (16 mg, 20%) as a white solid; ¹H NMR (MeOH-*d*₄) δ 8.07–8.04 (m, 2H), 7.66–7.61 (m, 1H), 7.52–7.48 (m, 2H), 6.19 (t, *J* = 6.6 Hz, 1H), 5.10 (d, *J* = 3.3 Hz, 1H), 4.62–4.44 (m, 3H), 4.13–4.11 (m, 1H), 2.76–2.72 (m, 1H), 2.32–2.28 (m, 1H), 2.22–2.19 (m, 1H), 1.04 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (MeOH-*d*₄) 173.9, 168.0, 154.4, 134.7, 131.3, 130.8, 129.9, 86.7, 85.3, 78.0, 72.6, 65.9, 42.6, 40.2, 10.6; IR (film) 3417, 2924, 1714, 1472, 1276, 1251, 711; HR-MS (FAB) calcd (M + H) 365.1349, found 365.1347.

6S-5,6-Dihydro-6-hydroxy-2'-deoxyuridine (8). Using the same procedure for the reduction of **15** (see below), 5,6-dihydro-5-bromo-6-hydroxy-2'-deoxyuridine (**14**, 75 mg, 0.17 mmol) was treated with zinc dust (66 mg, 1.0 mmol) in acetic acid (19 mg, 0.31 mmol). The crude product was purified via silica gel flash chromatography (1–6% MeOH/CHCl₃) to afford **8** (42 mg, 63% overall) as a white foam; ¹H NMR (MeOH-*d*₄) δ 8.06–8.04 (m, 2H), 7.65–7.60 (m, 1H), 7.52–7.47 (m, 2H), 6.23 (t, *J* = 6.0 Hz, 1H), 5.31 (dd, *J* = 3.9, 2.1 Hz, 1H), 4.56–4.41 (m, 3H), 4.07 (dd, *J* = 9.3, 4.2 Hz, 1H), 2.77 (dd, *J* = 16.8, 3.9 Hz, 1H), 2.54–2.44 (m, 2H), 2.18–2.10 (m, 1H); ¹³C NMR (MeOH-*d*₄) δ 174.3, 171.3, 167.9, 153.7, 134.6, 131.2, 130.8, 129.9, 85.7, 84.5, 73.1, 72.4, 65.7, 40.7, 38.7; IR (film) cm⁻¹ 3392, 1700, 1472, 1274, 1067, 711 cm⁻¹.

6R-5,6-Dihydro-6-hydroxy-2'-deoxyuridine (9). To a solution of 5,6-dihydro-5-bromo-6-hydroxy-2'-deoxyuridine (**15**, 75 mg, 0.17 mmol) in 3:1 THF/H₂O at 0 °C was added zinc dust (66 mg, 1.0 mmol) and acetic acid (19 mg, 0.31 mmol). The reaction was stirred 20 min at 0 °C, filtered through Celite and concentrated at ambient temperature. The crude reaction mixture was purified via silica gel flash chromatography (1–6% MeOH/CHCl₃) to afford an 11.5:1 mixture of **9** and 5'-benzoyl-2'-deoxyuridine (**11**, 42 mg, 63% overall) as a white

foam; ¹H NMR (MeOH-*d*₄) δ 8.05–8.01 (m, 2H), 7.65–7.59 (m, 1H), 7.51–7.47 (m, 2H), 6.17 (t, *J* = 6.9 Hz, 1H), 3.52 (dd, *J* = 4.1, 2.1 Hz, 1H), 4.53–4.41 (m, 3H), 4.10 (dd, *J* = 9.0, 4.5 Hz), 2.82 (dd, *J* = 17, 4.1 Hz, 1H), 2.53 (dd, *J* = 17, 2.1 Hz, 1H) 2.35–2.28 (m, 1H), 2.21–2.16 (m, 1H); ¹³C NMR (MeOH-*d*₄) δ 171.4, 168.0, 153.9, 142.1, 134.6, 131.2, 130.7, 129.8, 86.9, 85.3, 74.5, 72.6, 65.9, 39.8; IR (film) 3446, 1700, 1472, 1275, 1069, 757 cm⁻¹.

5-Benzoyl-2-deoxyribonolactone (17). To a solution of 2-deoxyribonolactone²⁰ (230 mg, 1.74 mmol) and Et₃N (229 mg, 2.26 mmol) in DMF (15 mL) at –40 °C was added benzoyl cyanide (274 mg, 2.09 mmol). The reaction was stirred overnight and allowed to warm to ambient temperature. The reaction was quenched with H₂O (4 mL), diluted with EtOAc (50 mL), washed with H₂O (3 × 50 mL), brine (50 mL) dried over Na₂SO₄, and concentrated. The crude product was purified via silica gel flash chromatography (1:2–1:1, EtOAc/hexanes) to afford **17** (127 mg, 31%) as a clear oil. ¹H NMR (CDCl₃) δ 7.99–7.96 (m, 2H), 7.62–7.57 (m, 1H), 7.48–7.45 (m, 2H), 4.70–4.68 (m, 1H), 4.61–4.55 (m, 3H), 3.08 (s, *J* = 3 Hz, 1H), 2.95 (dd, *J* = 18, 6.9 Hz, 1H), 2.62 (dd, *J* = 18 Hz, 3.9 Hz, 1H), IR (film) 3461, 2950, 1601, 1451, 1781, 1720, 1176, 1164, 1026, 944 cm⁻¹.

5'-Benzoyl-2'-deoxyribose (16). A toluene solution of DIBAL (2.0 mL, 1.0 M.) was added via syringe pump overnight to a solution of **17** (496 mg, 2.09 mmol) in CH₂Cl₂ (20 mL) maintained at –78 °C. The reaction was quenched while cold with MeOH (1 mL) and allowed to warm to ambient temperature. The reaction mixture was diluted with CH₂Cl₂ (80 mL) and washed with saturated Rochelle salt solution (100 mL), brine (100 mL), and concentrated in vacuo. The crude residue was purified via silica gel flash chromatography (1:3–1:1 EtOAc/CH₂Cl₂) to afford both anomers of **16** (22 mg, 4.4%) as a clear oil. ¹H NMR (CDCl₃) δ 8.07–8.00 (m, 2H), 7.60–7.54 (m, 1H), 7.46–7.41 (m, 2H), 5.64 (t, *J* = 4.5 Hz, 1H), 4.58–4.54 (m, 1H), 4.49 (d, *J* = 5.1 Hz, 0.6H), 4.37–4.32 (m, 2H), 4.20 (q, *J* = 5.1 Hz, 0.4H), 3.71 (d, *J* = 5.1 Hz, 0.7H), 3.48 (s, 0.3 Hz), 3.11 (d, *J* = 8.1 Hz, 0.7H), 2.47 (s, 0.3H), 2.98–2.14 (m, 2H); ¹³C NMR (CDCl₃) δ 166.9, 166.6, 133.5, 129.9, 129.8, 128.7, 99.6, 98.9, 85.3, 73.5, 72.6, 65.8, 64.8, 42.5, 41.5; IR (film) 3418, 2926, 1715, 1468, 1385, 1277, 1070, 1026 cm⁻¹; ESI-MS, 237.1 (M–H).

Analysis of pyrimidine hydrate decomposition. Aliquots were taken at appropriate times from a 1 mM solution (95/5 20 mM KH₂PO₄/CH₃CN) of the respective pyrimidine hydrate maintained at 37 or 90 °C. An internal standard (10 μL of a 1 mM solution of **10** for 2'-deoxyuridine hydrates, *p*-methoxybenzyl alcohol for thymidine hydrates) was added and the samples were diluted with 1:1 40 mM KH₂PO₄, pH 6.0/CH₃CN to inhibit further decomposition.

¹H NMR analysis of 2'-deoxyuridine hydrate epimerization. Hydrate **8** or **9** (10 mg, 0.028 mmol) and internal standard (*i*-PrOH, 0.3 mg, 0.005 mmol) were dissolved in 2.8:1 D₂O/CD₃CN (0.95 mL). Samples were placed in

NMR tubes and incubated in a 37°C bath. ¹H NMR spectra were collected at appropriate time intervals. The rate of epimerization was determined by observing the change in integration of the C-6 hydrogen peaks (δ 5.29 for 9, δ 5.22 for 8).

Acknowledgements

Financial support of this work from the National Institutes of Health (GM-54996) is appreciated. Mass spectra were obtained on instruments supported by the National Institutes of Health shared instrumentation grant (GM-49631).

References and Notes

1. von Sonntag, C. *The Chemical Basis of Radiation Biology*; Taylor & Francis: New York, 1987.
2. Barvian, M. R.; Barkley, R. M.; Greenberg, M. M. *J. Am. Chem. Soc.* **1995**, *117*, 4894.
3. Fisher, G. J.; Johns, H. E. In *Photochemistry & Photobiology of Nucleic Acids*; Wang, S. Y., Ed.; Academic: New York, 1976; Vol. 1, pp 169–224.
4. Cadet, J.; Vigny, P. In *Bioorganic Photochemistry*; Morrison, H., Ed.; Wiley Interscience: New York, 1990; Vol. 1, pp 1–272.
5. Boorstein, R. J.; Hilbert, T. P.; Cadet, J.; Cunningham, R. P.; Teebor, G. W. *Biochemistry* **1989**, *28*, 6164.
6. Boorstein, R. J.; Hilbert, T. P.; Cunningham, R. P.; Teebor, G. W. *Biochemistry* **1990**, *29*, 10455.
7. O'Donnell, R. E.; Boorstein, R. J.; Cunningham, R. P.; Teebor, G. W. *Biochemistry* **1994**, *33*, 9875.
8. Shaw, A. A.; Voituriez, L.; Cadet, J.; Gregoli, S.; Symons, M. C. R. *J. Chem. Soc., Perkin Trans.* **1988**, *2*, 1303.
9. David, S. S.; Williams, S. D. *Chem. Rev.* **1998**, *99*, 1221.
10. Dizdaroglu, M.; Bauche, C.; Rodriguez, H.; Laval, J. *Biochemistry* **2000**, *39*, 5586.
11. Ganguly, T.; Duker, N. J. *Nucleic Acids Res.* **1991**, *19*, 3319.
12. Ganguly, T.; Weems, K. M.; Duker, N. J. *Biochemistry* **1990**, *29*, 7222.
13. Greenberg, M. M.; Matray, T. J. *Biochemistry* **1997**, *36*, 14071.
14. Raoul, S.; Bardet, M.; Cadet, J. *Chem. Res. Toxicol.* **1995**, *8*, 924.
15. Cadet, J.; Teoule, R. *Carbohydrate Res.* **1973**, *29*, 345.
16. Cadet, J.; Ducolomb, R.; Teoule, R. *Tetrahedron* **1977**, *33*, 1603.
17. Cadet, J.; Kan, L.-S.; Wang, S. Y. *J. Am. Chem. Soc.* **1978**, *100*, 6715.
18. Wagner, J. R.; van Lier, J. E.; Berger, M.; Cadet, J. *J. Am. Chem. Soc.* **1994**, *116*, 2235.
19. Hruska, F. E.; Sebastian, R.; Grand, A.; Voituriez, L.; Cadet, J. *Can. J. Chem.* **1987**, *65*, 2618.
20. Deriaz, R. E.; Overend, W. G.; Stacey, M.; Teece, E. G.; Wiggins, L. F. *J. Chem. Soc.* **1949**, 1879.